VRT106
AXP000128.1 · Oncolytic virus
- Platform
- oncolytic alphavirus M1 (recombinant)
- Originator
- Sun Yat-sen University
- Sponsor
- Guangzhou Virotech Pharmaceutical
Names
Virus
- Role
- Oncolytic
- Family
- Togaviridae
- Virus
- Getah virus (NCBI Taxonomy 59300)
- Strain
- oncolytic virus M1 (VRT106)
- Replication
- replicating
- Modifications
- recombinant M1 alphavirus; details not disclosed
- Route
- intratumoral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (9)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07589244 | A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC | Recruiting | Phase 2/3 | 2026-05-13 | 2028-12-31 | 66 | HCC |
| NCT07589257 | A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma | Recruiting | Phase 2 | 2026-05-07 | 2028-06-30 | 10 | Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant |
| NCT07486310 | Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial | Not yet recruiting | Phase 2 | 2026-03-01 | 2028-03-01 | 30 | Advanced Gastric Cancer |
| NCT07093814 | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | Recruiting | Phase 1/2 | 2025-09-02 | 2028-12-31 | 42 | Glioblastoma |
| NCT06826313 | A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2025-03-19 | 2028-12-30 | 12 | Solid Tumors |
| NCT06758544 | A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer | Recruiting | Phase 1/2 | 2025-03-17 | 2026-09-30 | 18 | Pancreatic Cancer |
| NCT06866977 | A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer | Not yet recruiting | Phase 1/2 | 2025-03-12 | 2025-10-31 | 10 | Pancreatic Cancer |
| NCT06368921 | A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors | Recruiting | Phase 1 | 2024-06-19 | 2027-09 | 30 | Solid Tumor |
| NCT04665362 | IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC | Unknown | Phase 1 | 2021-01-25 | 2022-06-01 | 10 | Advanced/Metastatic Hepatocellular Carcinoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
No confirmed other papers yet.
Unconfirmed matches (29)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41781696 | Oncolytic virus M1 reinvigorates CD8+ T-cell immunity against glioblastoma through B-cell-dependent antigen cross-presentation in the spleen. | Cellular & molecular immunology | 2026 | name in title: oncolytic virus M1 |
| PMID 41903911 | Investigating oncolytic virus M1-Associated vesicles using 3D electron microscopy. | Journal of structural biology | 2026 | name in title: oncolytic virus M1 |
| PMID 41964220 | Identification of YBX1 as an essential host RNA-binding protein governing tumor-selective replication of oncolytic virus M1. | Molecular therapy : the journal of the American Society of Gene Therapy | 2026 | name in title: oncolytic virus M1 |
| PMID 42178397 | Sirolimus potentiates oncolytic Virus M1 efficacy through tumor-selective augmentation of viral replication. | Acta pharmacologica Sinica | 2026 | name in title: oncolytic virus M1 |
| PMID 42369044 | Clinical dose of enoxaparin enhances oncolytic virus M1 infection and antitumor efficacy in human bladder cancer. | iScience | 2026 | name in title: oncolytic virus M1 |
| PMID 39866243 | circ-1584 selectively promotes the antitumor activity of the oncolytic virus M1 on pancreatic cancer. | Molecular therapy. Oncology | 2025 | name in title: oncolytic virus M1 |
| PMID 41053536 | Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1. | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2025 | name in title: oncolytic virus M1 |
| PMID 41136390 | Retraction Note: DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. | Nature communications | 2025 | name in title: oncolytic virus M1 |
| PMID 41238218 | TAMs-mediated resistance to oncolytic virus M1 in solid tumors. | Journal for immunotherapy of cancer | 2025 | name in title: oncolytic virus M1 |
| PMID 38817541 | Enhancing antitumor efficacy of oncolytic virus M1 via albendazole-sustained CD8+ T cell activation. | Molecular therapy. Oncology | 2024 | name in title: oncolytic virus M1 |
| PMID 38828147 | Pharmacokinetic enhancement of oncolytic virus M1 by inhibiting JAK‒STAT pathway. | Acta pharmaceutica Sinica. B | 2024 | name in title: oncolytic virus M1 |
| PMID 37820722 | Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. | Cell reports. Medicine | 2023 | name in title: oncolytic virus M1 |
| PMID 37864032 | STT3A-mediated viral N-glycosylation underlies the tumor selectivity of oncolytic virus M1. | Oncogene | 2023 | name in title: oncolytic virus M1 |
| PMID 35393389 | Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. | Signal transduction and targeted therapy | 2022 | name in title: oncolytic virus M1 |
| PMID 35552024 | Overcoming resistance to oncolytic virus M1 by targeting PI3K-γ in tumor-associated myeloid cells. | Molecular therapy : the journal of the American Society of Gene Therapy | 2022 | name in title: oncolytic virus M1 |
| PMID 33338804 | Suppression of CCDC6 sensitizes tumor to oncolytic virus M1. | Neoplasia (New York, N.Y.) | 2021 | name in title: oncolytic virus M1 |
| PMID 34086978 | Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells. | International journal of cancer | 2021 | name in title: oncolytic virus M1 |
| PMID 32829653 | Systematic Characterization of the Biodistribution of the Oncolytic Virus M1. | Human gene therapy | 2020 | name in title: oncolytic virus M1 |
| PMID 33037696 | Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1. | Molecular oncology | 2020 | name in title: oncolytic virus M1 |
| PMID 33311488 | Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. | Cell death & disease | 2020 | name in title: oncolytic virus M1 |
| PMID 30604617 | Liposome Encapsulation of Oncolytic Virus M1 To Reduce Immunogenicity and Immune Clearance in Vivo. | Molecular pharmaceutics | 2019 | name in title: oncolytic virus M1 |
| PMID 29263275 | Deficiency of the IRE1α-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1. | Journal of virology | 2018 | name in title: oncolytic virus M1 |
| PMID 29449555 | Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer. | Cell death & disease | 2018 | name in title: oncolytic virus M1 |
| PMID 30337542 | DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. | Nature communications | 2018 | name in title: oncolytic virus M1 |
| PMID 28445966 | Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity. | Oncotarget | 2017 | name in title: oncolytic virus M1 |
| PMID 28607091 | Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. | Proceedings of the National Academy of Sciences of the United States of America | 2017 | name in title: oncolytic virus M1 |
| PMID 28835517 | Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. | Science translational medicine | 2017 | name in title: oncolytic virus M1 |
| PMID 26373347 | Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1. | Molecular therapy : the journal of the American Society of Gene Therapy | 2016 | name in title: oncolytic virus M1 |
| PMID 27296553 | Naturally Existing Oncolytic Virus M1 Is Nonpathogenic for the Nonhuman Primates After Multiple Rounds of Repeated Intravenous Injections. | Human gene therapy | 2016 | name in title: oncolytic virus M1 |
Notes
Recombinant oncolytic virus M1, a Getah-like alphavirus; phase 1 of intratumoral injection in advanced solid tumours (NCT06368921). Taxonomy assigned to Getah virus is the curator's best match and is not confirmed by the sponsor.
How to cite
VRT106 (AXP000128.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000128.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.